EU regulator starts a review of Russia’s COVID-19 vaccine

The European Medicines Agency (EMA) said in a statement it would review data from ongoing trials of the vaccine until there was enough evidence for a formal marketing authorisation application.

EMA’s ‘rolling reviews’ are aimed at speeding up the approval process by allowing researchers to submit findings in real-time before final trial data is ready.

“While EMA cannot predict the overall timelines, it should take less time than normal to evaluate an eventual application because of the work done during the rolling review,” it said.

Kirill Dmitriev, CEO of the RDIF sovereign wealth fund that is promoting Sputnik V internationally, hailed the start of EMA’s rolling review as an important moment for Russia which he said showed its application had been a strong one.

“Sputnik V can act as a bridge between Russia and Europe, but its roll out should not get bogged down in politics,” Dmitriev told Reuters, praising Germany, France, Italy and Austria for what he called their pragmatic approach to Sputnik V.

The shot’s efficacy was initially greeted with scepticism by some Western scientists after Russia approved it in August last year without waiting for the results of full clinical trials.

However, some of those initial concerns appear to have faded after scientists said it was almost 92% effective in fighting COVID-19, based on peer-reviewed late-stage trial results published in The Lancet medical journal last month.

The two-shot vaccine uses two different weakened common cold viruses to deliver immune-building protein to the human body.

Dmitriev said Moscow could provide vaccines for 50 million Europeans starting from June if the shot won EU-wide approval, adding he expected several EU countries to approve the use of Sputnik V this month for their national use.

He did not name the countries.

Europe has so far approved vaccines from Pfizer/BioNTech, Moderna and AstraZeneca/Oxford, while ongoing reviews for CureVac and Novavax’s candidates are underway.

The EMA is expected to give its verdict on J&J’s single-shot vaccine on March 11.